May 2, 2026 — The U.S. Food and Drug Administration (FDA) has approved expanded access to daraxonrasib, a targeted pancreatic cancer drug, allowing more patients to use the medication before its formal market approval. This is the world’s first RAS gene mutation inhibitor, and clinical trials have demonstrated its potential to significantly extend survival in metastatic pancreatic cancer patients.

A Breakthrough for the “King of Cancers”

Pancreatic cancer is known as the “king of cancers” — one of the most aggressive malignancies with a five-year survival rate of less than 10%. Over 90% of pancreatic cancer patients carry KRAS gene mutations, a target long considered “undruggable.”

Daraxonrasib, developed by Revolution Medicines, is the first drug to demonstrate in clinical trials that it can effectively inhibit KRAS mutations and extend survival in pancreatic cancer patients. In Phase II trials, patients receiving the drug showed significantly improved median survival compared to historical controls.

Expanded Access Program

The FDA’s expanded access approval allows critically ill patients who cannot benefit from other treatments to use the drug before formal market approval. This decision means eligible pancreatic cancer patients can gain earlier access to this innovative therapy.

Notably, the wife of former Senator Ben Sasse is among the early beneficiaries of the drug. The Sasse family has publicly supported the drug’s development and shared positive responses on social media.

Scientific Breakthrough

RAS proteins play a critical role in cell signaling, and their mutations drive uncontrolled cancer cell growth. For decades, scientists struggled to develop RAS-targeting drugs because the protein’s smooth structure lacked traditional drug-binding sites, making it seem nearly impossible to target.

In recent years, advances in structural biology and drug design have finally enabled strategies to target specific RAS mutations (such as KRAS G12C and G12D). Daraxonrasib is the product of this scientific breakthrough.

Next Steps in Approval

Revolution Medicines is currently advancing daraxonrasib through Phase III clinical trials. If results meet expectations, the company expects to submit a New Drug Application (NDA) to the FDA within 12-18 months.

Wall Street analysts are optimistic about the drug’s commercial prospects. Pancreatic cancer affects over 500,000 new patients globally each year, and effective targeted treatment options remain extremely limited. If approved, daraxonrasib is projected to generate billions in annual revenue.

Medical Community Response

The American Society of Clinical Oncology (ASCO) issued a statement calling daraxonrasib’s progress “one of the most breakthrough developments in pancreatic cancer treatment.” Oncology experts at UW Health expressed enthusiasm for the drug’s potential in interviews.

Sources: The Washington Post, Reuters, CBS News